A Phase 1 Study Of PF-00868554 In Hepatitis C Virus (HCV) Positive Patients

A Phase 1, Randomized, Double Blind (3rd Party Open), Placebo-controlled, Sequential Group, Multicentre Study To Evaluate The Multiple Dose Safety, Tolerability, Pharmacokinetics And Pharmacodynamics, of PF-00868554 in Hepatitis C Virus (HCV) Positive Otherwise Healthy Patient Volunteers

Assess the safety, tolerability and pharmacokinetics of multiple oral doses of PF-00868554 in HCV positive patient volunteers

Inclusion Criteria:

• HCV RNA ≥ 100,000 IU/mL at screening
• Genotype 1a or 1b

Exclusion Criteria:

• Current or prior treatment with IFN and/or RBV
• Evidence of decompensated liver disease